drugset
drugset / Trial / NCT07693426

Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

NCT07693426 ↗

Phase 1 Not yet recruiting 36 enrolled Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase Ib, randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Efsubaglutide Alfa Injection following multiple-dose administration in Chinese adolescent participants with obesity.

Timeline

Start
2026-07-10
Primary completion
2027-04-30
Completion
2027-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Efsubaglutide Alfa Protein / enzyme biologic 5 mg Subcutaneous
Subject Efsubaglutide Alfa Protein / enzyme biologic 10 mg Subcutaneous
Subject Efsubaglutide Alfa Protein / enzyme biologic 20 mg Subcutaneous

Indications

No indication recorded.